Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, January 26, 2021
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
[ Tue, Jan 26th 2021
] - WOPRAI
Mon, January 25, 2021
[ Mon, Jan 25th 2021
] - WOPRAI
[ Mon, Jan 25th 2021
] - WOPRAI
[ Mon, Jan 25th 2021
] - WOPRAI
[ Mon, Jan 25th 2021
] - WOPRAI
[ Mon, Jan 25th 2021
] - WOPRAI
Do Kim Downgraded (ALNY) to Hold and Held Target at $185 on, Jan 25th, 2021
Do Kim of BMO Capital, Downgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Hold and Held Target at $185 on, Jan 25th, 2021.
Do has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 1 agrees with Do's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $93 on, Wednesday, November 25th, 2020
This is the rating of the analyst that currently disagrees with Do
- David Lebovitz of "Morgan Stanley" Maintained at Buy with Increased Target to $203 on, Wednesday, November 25th, 2020
